IP Library › Granted Patent US 11,311,521
Granted Patent B2
US 11,311,521 · App. 17/468,457 · Granted Apr 26, 2022

Solid dispersion forms of rifaximin

Inventors: Pam Golden (Durham, NC); Mohammed A. Kabir (Cary, NC)
Assignee: Salix Pharmaceuticals, Inc.
A61K31/437A61K9/00A61K9/10A61K9/2853A61K9/2866A61K47/02A61K47/10A61K47/12A61K47/38A61P1/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,311,521
App. No.
17/468,457
Granted
Apr 26, 2022
Kind
B2
Abstract

Provided herein are solid dispersions comprising rifaximin and pharmaceutical compositions and uses thereof.

Claims (6)

1. A method of preventing complications of liver disease in a subject having liver cirrhosis, comprising administering to the subject an immediate release pharmaceutical composition comprising from about 16 wt % to about 18 wt % rifaximin and from about 16 wt % to about 18 wt % HPMC-AS, wherein the total amount of rifaximin is 40 mg and wherein the complications of liver disease are selected from the group consisting of hepatic encephalopathy (HE), esophageal variceal bleeding (EVB), spontaneous bacterial peritonitis (SBP), and hepatorenal syndrome (HRS).

2. The method of claim 1 , wherein the composition is in the form of a tablet.

3. The method of claim 1 , wherein the complication of liver disease is hepatic encephalopathy (HE).

4. The method of claim 1 , wherein the complication of liver disease is esophageal variceal bleeding (EVB).

5. The method of claim 1 , wherein the complication of liver disease is spontaneous bacterial peritonitis (SBP).

6. The method of claim 1 , wherein the complication of liver disease is hepatorenal syndrome (HRS).

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
SECURITY AGREEMENT (SECOND LIEN) Recorded Oct 5, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061606/0468 →
SECURITY AGREEMENT (FIRST LIEN) Recorded Oct 4, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061595/0066 →
SECURITY INTEREST Recorded Mar 30, 2022
From: BAUSCH+LOMB IRELAND LIMITED; BAUSCH HEALTH IRELAND LIMITED; BAUSCH & LOMB INCORPORATED; SALIX PHARMACEUTICALS, INC.
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 059446/0670 →
SECURITY INTEREST Recorded Mar 30, 2022
From: BAUSCH+LOMB IRELAND LIMITED; BAUSCH HEALTH IRELAND LIMITED; BAUSCH & LOMB INCORPORATED; SALIX PHARMACEUTICALS, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 059446/0722 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 6, 2021
From: GOLDEN, PAM; KABIR, MOHAMMED A.
To: SALIX PHARMACEUTICALS, LTD.
Reel/Frame 058305/0614 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 6, 2021
From: SALIX PHARMACEUTICALS, LTD.
To: SALIX PHARMACEUTICALS, INC.
Reel/Frame 058305/0683 →